For thousands of cancer patients, a diagnosis is followed by another difficult reality, finding a treatment they can actually afford. Over the past decade, nivolumab has changed the outlook for many people battling advanced cancers. It has helped patients live longer, reduced the risk of disease progression, and, in some cases, delivered long-lasting responses that were once considered impossible.
But while the medicine transformed cancer treatment, its high price has remained a challenge for patients, hospitals, and healthcare systems worldwide.
Now, the approaching patent expiry of nivolumab is creating a new chapter. It is no longer just a legal milestone for pharmaceutical companies. It represents an opportunity for lower-cost biosimilars, wider patient access, stronger market competition, and significant savings for healthcare systems around the world.
From Scientific Breakthrough to a Global Cancer Therapy
When nivolumab was first approved in 2014, it introduced a completely different way of treating cancer.
Unlike chemotherapy, which attacks rapidly growing cells, nivolumab works by helping the immune system recognize and fight cancer. It blocks the PD-1 (Programmed Death-1) pathway—a mechanism many tumors use to hide from immune cells.
Once this “immune brake” is removed, the body’s T-cells can once again identify and attack cancer cells.
Today, nivolumab is approved across dozens of treatment settings, including melanoma, non-small cell lung cancer (NSCLC), kidney cancer, liver cancer, bladder cancer, head and neck cancer, gastric cancer, esophageal cancer, colorectal cancer with MSI-H/dMMR, Hodgkin lymphoma, and several combination therapies.
Few cancer medicines have expanded into so many disease areas within a decade.
A Medicine Trusted Around the World
The widespread adoption of nivolumab reflects its clinical value.
More than 3 million patients worldwide have received treatment with nivolumab-based therapies since its launch, according to Bristol Myers Squibb.
The medicine is approved in more than 65 countries, and it has become a standard treatment recommendation in numerous international oncology guidelines.
Its commercial success has been equally remarkable.
In 2025, Opdivo (nivolumab) generated approximately US$9 billion in global sales, making it one of the world’s highest-selling cancer medicines.
Since its launch, cumulative worldwide revenue has exceeded US$75 billion, highlighting both its extensive use and the growing demand for immunotherapy.
Looking for answers to your specific business questions? Our experts provide FREE customized sample reports: https://www.towardshealthcare.com/download-sample/5432
Nivolumab at a Glance
| Category | Statistics |
|---|---|
| First regulatory approval | 2014 |
| Drug class | PD-1 immune checkpoint inhibitor |
| Brand name | Opdivo |
| Manufacturer | Bristol Myers Squibb |
| Countries approved | 65+ |
| Patients treated globally | More than 3 million |
| Global sales (2025) | Around US$9 billion |
| Estimated cumulative sales | Over US$75 billion |
| Approved cancer indications | More than 10 major cancers |
Why Patent Expiry Matters More Than Most People Think
Every innovative medicine is protected by patents that allow companies to recover years of research and development investment.
For biologic medicines like nivolumab, patent protection is more complex than for traditional drugs. Instead of relying on a single patent, manufacturers typically hold multiple patents covering the molecule, manufacturing process, formulations, methods of treatment, and delivery technologies.
As these protections begin expiring in different countries over the coming years, biosimilar manufacturers will gain opportunities to enter the market.
Unlike traditional generic medicines, biosimilars are not exact copies. They are highly similar versions of biological medicines that must demonstrate comparable safety, effectiveness, quality, and clinical performance before receiving regulatory approval.
Cancer Cases Are Rising Faster Than Ever
The importance of affordable immunotherapy becomes clearer when looking at the global cancer burden.
According to the World Health Organization (WHO):
- Around 20 million new cancer cases were diagnosed worldwide in 2022.
- Nearly 9.7 million people died from cancer in the same year.
- Approximately 1 in 5 people will develop cancer during their lifetime.
- Around 1 in 9 men and 1 in 12 women die from cancer globally.
The International Agency for Research on Cancer (IARC) also projects that annual cancer cases will increase to more than 35 million by 2050, representing a 77% increase compared to 2022.
As cancer continues to rise worldwide, demand for advanced treatments such as nivolumab will grow significantly.
Why Healthcare Systems Are Waiting for Biosimilars
Cancer medicines account for one of the fastest-growing areas of healthcare spending.
According to the IQVIA Institute, global spending on oncology medicines exceeded US$223 billion in 2023, nearly doubling over the previous decade.
At the same time, biologic medicines account for only a small proportion of prescriptions but represent a disproportionately large share of pharmaceutical spending because of their high development and manufacturing costs.
This is why governments across North America, Europe, and Asia continue encouraging biosimilar adoption to improve access while controlling healthcare expenditure.
Lower Prices Could Mean More Patients Receive Treatment
History shows what happens when biosimilars enter the market.
Across several biologic therapies, biosimilar competition has reduced treatment prices by 15% to 40%, while some highly competitive markets have reported even larger price reductions.
For hospitals, these savings often translate into treating more patients using the same oncology budget.
For patients, lower prices may reduce financial barriers, improve insurance reimbursement, shorten waiting times, and expand access to life-saving immunotherapy.
In many low- and middle-income countries, where advanced immunotherapies remain beyond the reach of many patients, biosimilars could make these treatments substantially more accessible.
The Race to Develop Nivolumab Biosimilars Has Already Begun
Pharmaceutical companies are not waiting for every patent to expire.
Several global biosimilar developers have already initiated research, analytical studies, manufacturing programs, and clinical development for nivolumab biosimilars.
Developing a biosimilar is a lengthy and expensive process. Industry estimates suggest development typically requires 7–9 years and investments ranging from US$100 million to more than US$300 million for a single product.
Despite these costs, biosimilars are still considerably less expensive to develop than entirely new biologic medicines, making them an attractive opportunity as patent protections expire.
A New Era for Cancer Treatment
The story of nivolumab began as one of scientific innovation. It showed that empowering the immune system could dramatically improve outcomes for patients with some of the world’s deadliest cancers.
Its patent expiry now represents the beginning of another important story—one focused on affordability and access.
As biosimilars gradually enter global markets, healthcare systems could save billions of dollars, hospitals may be able to treat more patients, and millions of people who previously struggled to access immunotherapy may finally have a realistic chance of receiving it.
For patients, the real impact of nivolumab’s patent expiry will not simply be lower prices. It could mean earlier treatment, broader access, and better opportunities to fight cancer when every day matters.
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research and Consulting is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium